Palisade Bio (PALI) reported a net loss of $14.6 million, or $0.07 per basic and diluted share, for the third quarter ended September 30, 2026. The clinical-stage biopharmaceutical company reported $113.6 million in cash and cash equivalents at quarter-end.
The company dosed the first patient in its global Phase 2b ASCENTRA-UC trial of PALI-2108 on October 27 and said topline results from the 12-week induction period are expected in the fourth quarter of 2027. FDA clearance for the Phase 2a ASCENTRA-CD trial was received in September.
- Third-quarter research and development expense was $10.6 million, versus $1.4 million a year earlier.
- General and administrative expense totaled $5.1 million, compared with $1.5 million in the prior-year quarter.
- ASCENTRA-UC is expected to enroll about 204 patients across approximately 115 total sites.
- ASCENTRA-CD enrollment is targeted to begin in the first quarter of 2027, with a primary efficacy readout expected in the first quarter of 2028.
$PALI Insider Trading Activity
$PALI insiders have traded $PALI stock on the open market 10 times in the past 6 months. Of those trades, 8 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $PALI stock by insiders over the last 6 months:
- JOHN DAVID FINLEY (CEO, CFO) sold 146,798 shares for an estimated $303,343
- ROBERT JR. BALTERA has made 6 purchases buying 125,000 shares for an estimated $250,182 and 0 sales.
- MITCHELL LAWRENCE JONES (Chief Medical Officer) sold 51,880 shares for an estimated $106,535
- DONALD ALLEN WILLIAMS has made 2 purchases buying 20,000 shares for an estimated $28,800 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$PALI Hedge Fund Activity
We have seen 67 institutional investors add shares of $PALI stock to their portfolio, and 58 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SOLEUS CAPITAL MANAGEMENT, L.P. added 13,063,687 shares (+inf%) to their portfolio in Q2 2026, for an estimated $27,303,105
- BLACKROCK, INC. added 8,560,420 shares (+456.2%) to their portfolio in Q2 2026, for an estimated $17,891,277
- COMMODORE CAPITAL LP removed 7,181,062 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $15,008,419
- POINT72 ASSET MANAGEMENT, L.P. added 4,841,631 shares (+1175.8%) to their portfolio in Q2 2026, for an estimated $10,119,008
- AMERIPRISE FINANCIAL INC added 2,370,049 shares (+27.2%) to their portfolio in Q2 2026, for an estimated $4,953,402
- MARSHALL WACE, LLP removed 2,355,613 shares (-85.5%) from their portfolio in Q2 2026, for an estimated $4,923,231
- GREAT POINT PARTNERS LLC added 2,284,819 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,775,271
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
